Literature DB >> 22285687

Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Joseph G Dauner1, Yuanji Pan, Allan Hildesheim, Troy J Kemp, Carolina Porras, Ligia A Pinto.   

Abstract

Antibody responses against infectious agents are an important component in the prevention of disease. The avidity of antibodies for their antigens relates to their functional efficiency, and is a fundamental aspect in the investigation of humoral responses. Modified ELISAs are used to estimate avidity through the use of chaotropic agents and the measurement of the degree to which they disrupt the interaction between antibody and antigen. The theory behind the assay is the higher the avidity of an interaction the less susceptible it is to the effects of the chaotropic agent. The goal of this study was to generate a modified ELISA where a complex, multimeric coating-antigen, human papillomavirus (HPV) virus-like particles (VLP), was used to measure the avidity of anti-HPV antibodies generated following vaccination with HPV VLPs. A series of chaotropic agents were evaluated in the assay for their effectiveness in measuring avidity. Guanidine hydrochloride (GuHCl) was selected as a chaotropic reagent with the ability to disrupt antibody and antigen interactions, while not affecting the integrity of the plate-bound VLP. Two methods of determining the avidity index were assessed and shown to be comparable. This assay was then successfully applied to measure the avidity of anti-HPV VLP serum antibodies in samples from an HPV L1 VLP vaccine clinical trial. Overall, the assay was highly reproducible and captured a wide range of antibody avidities. Therefore, a GuHCl-modified ELISA is an acceptable method that can be used to determine HPV-specific antibody avidity indices within a clinical trial setting.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285687      PMCID: PMC3319198          DOI: 10.1016/j.mcp.2012.01.002

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  39 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines.

Authors:  V A de Souza; C S Pannuti; L M Sumita; H F de Andrade Júnior
Journal:  J Med Virol       Date:  1997-07       Impact factor: 2.327

3.  Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.

Authors:  K Raviprakash; K R Porter; T J Kochel; D Ewing; M Simmons; I Phillips; G S Murphy; W R Weiss; C G Hayes
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

4.  Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Authors:  C L Vermont; H H van Dijken; C J P van Limpt; R de Groot; L van Alphen; G P J M van Den Dobbelsteen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Absence of avidity maturation of autoantibodies to the protein tyrosine phosphatase-like IA-2 molecule and glutamic acid decarboxylase (GAD65) during progression to type 1 diabetes.

Authors:  Annette Westerlund; Matti Ankelo; Jorma Ilonen; Mikael Knip; Olli Simell; Ari E Hinkkanen
Journal:  J Autoimmun       Date:  2005-03       Impact factor: 7.094

6.  Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis.

Authors:  Lenka M Pereira Arias-Bouda; Sjoukje Kuijper; Anouk Van der Werf; Lan N Nguyen; Henk M Jansen; Arend H J Kolk
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

7.  The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

Authors:  D Chargelegue; C M Stanley; C M O'Toole; B T Colvin; M W Steward
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

8.  A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.

Authors:  Fernando P Polack; Scott J Hoffman; Gonzalo Crujeiras; Diane E Griffin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

9.  Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.

Authors:  Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

10.  Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody.

Authors:  K N Ward; W Dhaliwal; K L Ashworth; E J Clutterbuck; C G Teo
Journal:  J Med Virol       Date:  1994-08       Impact factor: 2.327

View more
  18 in total

1.  Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.

Authors:  Zhenwu Luo; Elizabeth Ogunrinde; Min Li; Lumin Zhang; Lisa Martin; Zejun Zhou; Zhiliang Hu; Tao Zhang; Zhen Li; Jiafeng Zhang; Bin Su; Tong Zhang; Hao Wu; Lei Ma; Guoyang Liao; Allison Ross Eckard; Maria Anna Julia Westerink; Sonya L Heath; Wei Jiang
Journal:  AIDS       Date:  2019-01-27       Impact factor: 4.177

2.  Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men.

Authors:  Ligia A Pinto; Timothy J Wilkin; Troy J Kemp; Martha Abrahamsen; Kimberly Isaacs-Soriano; Yuanji Pan; Jennifer Webster-Cyriaque; Joel M Palefsky; Anna R Giuliano
Journal:  Vaccine       Date:  2019-03-30       Impact factor: 3.641

3.  Silk-based blood stabilization for diagnostics.

Authors:  Jonathan A Kluge; Adrian B Li; Brooke T Kahn; Dominique S Michaud; Fiorenzo G Omenetto; David L Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

4.  Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism.

Authors:  Amir Bolandparvaz; Rian Harriman; Kenneth Alvarez; Kristina Lilova; Zexi Zang; Andy Lam; Elizabeth Edmiston; Alexandra Navrotsky; Natalia Vapniarsky; Judy Van De Water; Jamal S Lewis
Journal:  Nanomedicine       Date:  2019-07-23       Impact factor: 5.307

5.  Comparison of different enzyme-linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies.

Authors:  Lenka Fialová; Milada Petráčková; Oliver Kuchař
Journal:  J Clin Lab Anal       Date:  2017-01-26       Impact factor: 2.352

6.  The Aryl Hydrocarbon Receptor Modulates T Follicular Helper Cell Responses to Influenza Virus Infection in Mice.

Authors:  Cassandra L Houser; B Paige Lawrence
Journal:  J Immunol       Date:  2022-04-20       Impact factor: 5.426

7.  Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).

Authors:  Troy J Kemp; Mahboobeh Safaeian; Allan Hildesheim; Yuanji Pan; Kerri J Penrose; Carolina Porras; John T Schiller; Douglas R Lowy; Rolando Herrero; Ligia A Pinto
Journal:  Vaccine       Date:  2012-10-31       Impact factor: 3.641

8.  Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmette-Guérin Vaccination to Improve Antiviral Antibody Responses.

Authors:  Tony W Ng; Ariel S Wirchnianski; Anna Z Wec; J Maximilian Fels; Christopher T Johndrow; Kevin O Saunders; Hua-Xin Liao; John Chan; William R Jacobs; Kartik Chandran; Steven A Porcelli
Journal:  J Immunol       Date:  2020-06-08       Impact factor: 5.422

9.  Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Authors:  Mahboobeh Safaeian; Troy J Kemp; David Yuanji Pan; Carolina Porras; Ana Cecilia Rodriguez; Mark Schiffman; Bernal Cortes; Hormuzd Katki; Sholom Wacholder; John T Schiller; Paula Gonzalez; Kerri Penrose; Douglas R Lowy; Wim Quint; Leen-Jan van Doorn; Rolando Herrero; Allan Hildesheim; Ligia A Pinto
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

10.  BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.

Authors:  Federico Pratesi; Teresita Caruso; Davide Testa; Tiziano Tarpanelli; Alessandra Gentili; Davide Gioè; Paola Migliorini
Journal:  Vaccines (Basel)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.